153 related articles for article (PubMed ID: 25701195)
1. The novel multispecies Fc-specific Pseudomonas exotoxin A fusion protein α-Fc-ETA' enables screening of antibodies for immunotoxin development.
Klausz K; Kellner C; Derer S; Valerius T; Staudinger M; Burger R; Gramatzki M; Peipp M
J Immunol Methods; 2015 Mar; 418():75-83. PubMed ID: 25701195
[TBL] [Abstract][Full Text] [Related]
2. Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines.
Barth S; Huhn M; Wels W; Diehl V; Engert A
Int J Mol Med; 1998 Jan; 1(1):249-56. PubMed ID: 9852227
[TBL] [Abstract][Full Text] [Related]
3. CD30L-ETA': a new recombinant immunotoxin based on the CD30 ligand for possible use against human lymphoma.
Barth S; Matthey B; Huhn M; Diehl V; Engert A
Cytokines Cell Mol Ther; 1999 Jun; 5(2):69-78. PubMed ID: 10515679
[TBL] [Abstract][Full Text] [Related]
4. A deletion mutant of Pseudomonas exotoxin-A fused to recombinant human interleukin-9 (rhIL-9-ETA') shows specific cytotoxicity against IL-9-receptor-expressing cell lines.
Klimka A; Barth S; Drillich S; Wels W; van Snick J; Renauld JC; Tesch H; Bohlen H; Diehl V; Engert A
Cytokines Mol Ther; 1996 Sep; 2(3):139-46. PubMed ID: 9384698
[TBL] [Abstract][Full Text] [Related]
5. A new series of pET-derived vectors for high efficiency expression of Pseudomonas exotoxin-based fusion proteins.
Matthey B; Engert A; Klimka A; Diehl V; Barth S
Gene; 1999 Mar; 229(1-2):145-53. PubMed ID: 10095114
[TBL] [Abstract][Full Text] [Related]
6. Identification of epitopes on a mutant form of Pseudomonas exotoxin using serum from humans treated with Pseudomonas exotoxin containing immunotoxins.
Roscoe DM; Pai LH; Pastan I
Eur J Immunol; 1997 Jun; 27(6):1459-68. PubMed ID: 9209499
[TBL] [Abstract][Full Text] [Related]
7. Recombinant immunotoxins containing the VH or VL domain of monoclonal antibody B3 fused to Pseudomonas exotoxin.
Brinkmann U; Lee BK; Pastan I
J Immunol; 1993 Apr; 150(7):2774-82. PubMed ID: 8454854
[TBL] [Abstract][Full Text] [Related]
8. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo.
Azemar M; Schmidt M; Arlt F; Kennel P; Brandt B; Papadimitriou A; Groner B; Wels W
Int J Cancer; 2000 Apr; 86(2):269-75. PubMed ID: 10738256
[TBL] [Abstract][Full Text] [Related]
9. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line.
Klimka A; Barth S; Matthey B; Roovers RC; Lemke H; Hansen H; Arends JW; Diehl V; Hoogenboom HR; Engert A
Br J Cancer; 1999 Jun; 80(8):1214-22. PubMed ID: 10376974
[TBL] [Abstract][Full Text] [Related]
10. Monovalent immunotoxin containing truncated form of Pseudomonas exotoxin as potent antitumor agent.
Debinski W; Pastan I
Cancer Res; 1992 Oct; 52(19):5379-85. PubMed ID: 1394141
[TBL] [Abstract][Full Text] [Related]
11. Use of Pseudomonas aeruginosa toxin A in the construction of conjugate vaccines and immunotoxins.
Cryz SJ; Fürer E; Sadoff JC; Germanier R; Pastan I; Willingham MC; FitzGerald DJ
Rev Infect Dis; 1987; 9 Suppl 5():S644-9. PubMed ID: 3120274
[TBL] [Abstract][Full Text] [Related]
12. Immunotoxins containing Pseudomonas exotoxin A: a short history.
Pastan I
Cancer Immunol Immunother; 2003 May; 52(5):338-41. PubMed ID: 12700949
[No Abstract] [Full Text] [Related]
13. Generation of neutralizing antipeptide antibodies to the enzymatic domain of Pseudomonas aeruginosa exotoxin A.
Elzaim HS; Chopra AK; Peterson JW; Goodheart R; Heggers JP
Infect Immun; 1998 May; 66(5):2170-9. PubMed ID: 9573104
[TBL] [Abstract][Full Text] [Related]
14. Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice.
Benhar I; Pastan I
Clin Cancer Res; 1995 Sep; 1(9):1023-9. PubMed ID: 9816075
[TBL] [Abstract][Full Text] [Related]
15. B3(Fab)-PE38M: a recombinant immunotoxin in which a mutant form of Pseudomonas exotoxin is fused to the Fab fragment of monoclonal antibody B3.
Choe M; Webber KO; Pastan I
Cancer Res; 1994 Jul; 54(13):3460-7. PubMed ID: 8012967
[TBL] [Abstract][Full Text] [Related]
16. In vivo imaging of immunotoxin treatment using Katushka-transfected A-431 cells in a murine xenograft tumour model.
Pardo A; Stöcker M; Kampmeier F; Melmer G; Fischer R; Thepen T; Barth S
Cancer Immunol Immunother; 2012 Oct; 61(10):1617-26. PubMed ID: 22350071
[TBL] [Abstract][Full Text] [Related]
17. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin.
Batra JK; Kasprzyk PG; Bird RE; Pastan I; King CR
Proc Natl Acad Sci U S A; 1992 Jul; 89(13):5867-71. PubMed ID: 1352878
[TBL] [Abstract][Full Text] [Related]
18. A variant of exotoxin A that forms potent and specific chemically conjugated immunotoxins.
Chaudry GJ; Fulton RJ; Draper RK
J Biol Chem; 1993 May; 268(13):9437-41. PubMed ID: 8486636
[TBL] [Abstract][Full Text] [Related]
19. Design of a genetic immunotoxin to eliminate toxin immunogenicity.
Chen SY; Zani C; Khouri Y; Marasco WA
Gene Ther; 1995 Mar; 2(2):116-23. PubMed ID: 7719928
[TBL] [Abstract][Full Text] [Related]
20. Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha.
Schmidt M; Wels W
Br J Cancer; 1996 Sep; 74(6):853-62. PubMed ID: 8826849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
